Innovative Cancer Screening Program by Longevity Medical Institute
Longevity Medical Institute™ (LMI), recognized as a leader in regenerative medicine and advanced diagnostics, has announced a groundbreaking collaboration with OncoInv, a pioneer in multi-cancer early detection technology. This partnership, which utilizes OncoSeek® technology, marks a significant milestone in the fight against cancer, establishing one of the most advanced and accessible cancer screening programs available in Latin America.
The Efficacy of OncoSeek® Technology
Recent studies have highlighted the efficacy of OncoSeek® in detecting multiple cancer types at earlier stages. Research published in the clinical journal eClinicalMedicine emphasizes its ability to distinguish between healthy and cancerous samples effectively. The study showcased OncoSeek®'s impressive sensitivity of 51.7% alongside a specificity rate of 92.9%, achieving an overall accuracy of 84.3% across nine prevalent cancer types. This advancement not only enhances screening capabilities but also instills greater confidence in early detection efforts.
Integrating Advanced Diagnostics
At LMI, the integration of OncoSeek® into clinical practices has resulted in a uniquely robust cancer screening platform. This comprehensive system analyzes more than 70 critical biomarkers, including PSA Total, PSA Free, and CA 125, among others. By facilitating the detection of over 12 distinct cancer types, the program is backed by extensive scientific literature, enhancing the sensitivity for high-risk cancers. Such advancements promise improved patient outcomes through accurate and timely diagnosis.
Tailored Approach for Older Adults
With a primary focus on adults aged 50 and older, the collaboration between LMI and OncoInv is strategic and impactful. Dr. Kirk Sanford, Founder and CEO of Longevity Medical Institute, asserts that this partnership is crucial in delivering high-quality, personalized healthcare that not only aims to prolong life but also significantly improves the quality of life for patients.
Leading the Charge in Preventive Healthcare
As multi-cancer early detection (MCED) tools gain traction, LMI's approach stands out. While Galleri® by GRAIL has redefined the landscape in the U.S., the integration of OncoSeek® into LMI's comprehensive tumor marker panel delivers a solution that adapts seamlessly to the specific preventive healthcare needs encountered in Mexico.
The combined system ensures full coverage of the most deadly cancers, providing similar early-stage detection rates as leading U.S. technologies, confirming it as a vital and effective screening tool.
Enhancing Patient Experience through Technology
The collaboration enhances patient comfort with a streamlined approach where a single blood draw provides extensive insights. Unlike alternative cancer detection methods that typically require multiple visits, LMI's integrated solution allows for quicker, more comprehensive results, enabling clinicians to make informed decisions without unnecessary delays.
Commitment to Patient-Centric Care
Edward Ramsay, Director of Clinical Laboratory at LMI, emphasizes the institute's dedication to a patient-centric model. The innovative approach not only prioritizes convenience but also advocates for early intervention, empowered by advanced data analysis technology.
About Longevity Medical Institute™
Longevity Medical Institute, headquartered in San José del Cabo, operates within 15,000 square feet dedicated to regenerative medicine and diagnostics, blending advanced technologies with personalized healthcare solutions. With same-day lab results and guided care, LMI transforms patient experiences, placing emphasis on longevity and well-being.
Continued Innovations with OncoSeek®
OncoSeek®, developed by SeekIn Inc., stands as a state-of-the-art blood-based multi-cancer early detection test. It employs AI to analyze key tumor markers, providing invaluable insights into cancer origin and risk. Collaboratively, OncoSeek® and LMI are committed to revolutionizing cancer diagnostics, assuring patients have access to cutting-edge, non-invasive detection tools.
Frequently Asked Questions
What is the purpose of the collaboration between LMI and OncoInv?
This partnership aims to enhance cancer screening capabilities in Mexico, utilizing advanced technologies like OncoSeek® to detect multiple cancers early.
How does OncoSeek® work?
OncoSeek® analyzes protein tumor markers through a blood test, helping to identify cancer presence and origin through an AI-driven process.
What advantages does LMI's program offer patients?
Patients benefit from an integrated testing approach that utilizes a single blood draw, providing extensive results quickly and minimizing wait times.
Who can benefit from the new screening program?
The program primarily targets adults aged 50 and above, recognizing their increased cancer risk and need for regular screenings.
What should patients expect during the screening process?
Patients will undergo a simple blood draw, after which they can expect rapid turnaround times on their results, enabling timely interventions.
